European Chemicals Agency (ECHA) published a news release stating that the risk assessment of di(2-ethylhexyl)phthalate (DEHP) and dibutyl phthalate (DBP) shall be a guidance for future risk assessment of Substances of Very High Concern (SVHCs). ECHA published oral, dermal and inhalation Derived No Effect Levels (DNELs) for DEHP and DBP on April 12, 2013. The risk assessments were carried out by the Committee for Risk Assessment (RAC). They shall facilitate the evaluation of upcoming applications for authorization of substances on Annex XIV of the European Registration, Evaluation, Authorisation and Restriction of Chemical substances (REACH) regulation. Substances on Annex XIV have been prioritized for authorization by ECHA because of their serious and irreversible effects on human health and the environment. For Annex XIV substances, DNELs shall be derived before applications for authorization are received and shall serve as non-legally binding ‘reference’ values indicating to manufacturers how the RAC will evaluate their applications.
Read more
